Impact of variants within seven candidate genes on statin treatment efficacy

Physiological Research

Volumn 61, Issue 6, 2012, Pages 609-617

  Vrablik M ^a   Hubacek J A ^b   Dlouha D ^b   Lanska V ^b   Rynekrova J ^b   Zlatohlavek L ^a   Prusikova M ^a   Ceska R ^a   Adamkova V ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Efficacy; Genes; Polymorphisms; Statins

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

AGED; ALLELE; ARTICLE; BLOOD; DYSLIPIDEMIA; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; HUMAN GENOME; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

AGED; ALLELES; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GENETIC VARIATION; GENOME, HUMAN; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; TREATMENT OUTCOME;

EID: 84873839102     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ANGELOPOULOS TJ, LOWNDES J: ApoE genotype: impact on health, fitness and nutrition. World Rev Nutr Diet 98: 77-93, 2008.
2. AULCHENKO YS, RIPATTI S, LINDQVIST I, BOOMSMA D, HEID IM, PRAMSTALLER PP, PENNINX BW, JANSSENS AC, WILSON JF, SPECTOR T, MARTIN NG, PEDERSEN NL, KYVIK KO, KAPRIO J, HOFMAN A, FREIMER NB, JARVELIN MR, GYLLENSTEN U, CAMPBELL H, RUDAN I, JOHANSSON A, MARRONI F, HAYWARD C, VITART V, JONASSON I, PATTARO C, WRIGHT A, HASTIE N, PICHLER I, HICKS AA, FALCHI M, WILLEMSEN G, HOTTENGA JJ, DE GEUS EJ, MONTGOMERY GW, WHITFIELD J, MAGNUSSON P, SAHARINEN J, PEROLA M, SILANDER K, ISAACS A, SIJBRANDS EJ, UITTERLINDEN AG, WITTEMAN JC, OOSTRA BA, ELLIOTT P, RUOKONEN A, SABATTI C, GIEGER C, MEITINGER T, KRONENBERG F, DÖRING A, WICHMANN HE, SMIT JH, MCCARTHY MI, VAN DUIJN CM, PELTONEN L; ENGAGE CONSORTIUM: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 41: 47-55, 2009.
3. BERGER J: The age of biomedicine: current trends in traditional subjects. J Appl Biomed 9: 57-61, 2011.
4. DAY IN, HUMPHRIES SE: Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 222: 389-395, 1994.
5. HACHEM SB, MOORADIAN AD: Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 66: 1949-1969, 2006.
6. HAYMAN LL: Abnormal blood lipids: is it environment or is it genes? J Cardiovasc Nurs 14: 39-49, 2000
7. HUBACEK JA, VRABLIK M: Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact 26: 13-20, 2011.
8. HUBACEK JA, ADAMKOVA V, PRUSIKOVA M, SNEJDRLOVA M, HIRSCHFELDOVA K, LANSKA V, CESKA R, VRABLIK M: Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics 10: 945-950, 2009.
9. HUBÁČEK JA, ADÁMKOVÁ V, LÁNSKÁ V, DLOUHÁ D, RYNEKROVÁ J, ZLATOHLÁVEK L, PRUSÍKOVÁ M, ČEŠKA R, VRABLÍK M: Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. J Appl Biomed 10: 19-28, 2012.
10. KAJINAMI K, BROUSSEAU DE, ORDOVAS JM, SCHAEFER EJ: A promoter polymorphism in cholesterol 7alphahydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 180: 407-415, 2005.
11. KATHIRESAN S, MELANDER O, GUIDUCCI C, SURTI A, BURTT NP, RIEDER MJ, COOPER GM, ROOS C, VOIGHT BF, HAVULINNA AS, WAHLSTRAND B, HEDNER T, CORELLA D, TAI ES, ORDOVAS JM, BERGLUND G, VARTIAINEN E, JOUSILAHTI P, HEDBLAD B, TASKINEN MR, NEWTON-CHEH C, SALOMAA V, PELTONEN L, GROOP L, ALTSHULER DM, ORHO-MELANDER M: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40: 189-197, 2008. Erratum in: Nat Genet 40: 1348, 2008.
12. KJOLBY M, ANDERSEN OM, BREIDERHOFF T, FJORBACK AW, PEDERSEN KM, MADSEN P, JANSEN P, HEEREN J, WILLNOW TE, NYKJAER A: Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab 12: 213-223, 2010.
13. KOONER JS, CHAMBERS JC, AGUILAR-SALINAS CA, HINDS DA, HYDE CL, WARNES GR, GÓMEZ PÉREZ FJ, FRAZER KA, ELLIOTT P, SCOTT J, MILOS PM, COX DR, THOMPSON JF: Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 40: 149-151, 2008.
14. MAGGO SD, KENNEDY MA, CLARK DW: Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf 34: 1-19, 2011.
15. MANGRAVITE LM, KRAUSS RM: Pharmacogenetics of statin response. Curr Opin Lipidol 18: 409-419, 2007.
16. MANGRAVITE LM, MEDINA MW, CUI J, PRESSMAN S, SMITH JD, RIEDER MJ, GUO X, NICKERSON DA, ROTTER JI, KRAUSS RM: Combined influence of LDL and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol 30: 1485-1492, 2010.
17. MILLER SA, DYKES DD, POLESKY HF: A simple salting out procedure for DNA extraction from human nucleated cells. Nucleic Acid Res 16: 1215, 1988.
18. MUNAFÒ MR: Reliability and replicability of genetic association studies. Addiction 104: 1439-1440, 2009.
19. ORDOVAS JM, MOOSER V: The APOE locus and the pharmacogenetics of the lipid response. Curr Opin Lipidol 13: 113-117, 2002.
20. PITHA J, BOBKOVÁ D, KOVÁŘ J, HAVLÍČKOVÁ J, POLEDNE R: Antiatherogenic effect of simvastatin is not due to decrease of LDL cholesterol in ovariectomized golden Syrian hamster. Physiol Res 59: 401-406, 2010.
21. POLEDNE R, HUBÁČEK JA, STANĚK V, ASCHERMANN M, MATOUŠKOVÁ J, VESELKA J, WIDIMSKÝ P, CÍFKOVÁ R, LÁNSKÁ V, PIŤHA J: Why we are not able to find the coronary heart disease gene - apoE as an example. Folia Biol (Praha) 56: 218-222, 2010.
22. ROSENBERG NA, HUANG L, JEWETT EM, SZPIECH ZA, JANKOVIC I, BOEHNKE M: Genome-wide association studies in diverse populations. Nat Rev Genet 11: 356-366, 2010.
23. SADOWITZ B, MAIER KG, GATHAN V: Basic science review: Statin therapy - Part I: The pleiotropic effects of statins in cardiovascular dinase. Vasc Endovascular Surg 44: 241-251, 2010.
24. SANDHU MS, WATERWORTH DM, DEBENHAM SL, WHEELER E, PAPADAKIS K, ZHAO JH, SONG K, YUAN X, JOHNSON T, ASHFORD S, INOUYE M, LUBEN R, SIMS M, HADLEY D, MCARDLE W, BARTER P, KESÄNIEMI YA, MAHLEY RW, MCPHERSON R, GRUNDY SM; WELLCOME TRUST CASE CONTROL CONSORTIUM, BINGHAM SA, KHAW KT, LOOS RJ, WAEBER G, BARROSO I, STRACHAN DP, DELOUKAS P, VOLLENWEIDER P, WAREHAM NJ, MOOSER V: LDL-cholesterol concentrations: a genome-wide association study. Lancet 371: 483-491, 2008.
25. SEKI S, KAWAGUCHI Y, CHIBA K, MIKAMI Y, KIZAWA H, OYA T, MIO F, MORI M, MIYAMOTO Y, MASUDA I, TSUNODA T, KAMATA M, KUBO T, TOYAMA Y, KIMURA T, NAKAMURA Y, IKEGAWA S: A functional SNP in CILP, encoding the cartilage intermediate layer protein, is associated with susceptibility tolumbar disc disease. Nat Genet 37: 607-612, 2005.
26. SEVER PS, DAHLOF B, POULTER NR, WEDEL H, BEEVERS G, CAULFIELD M, COLLINS R, KJELDSEN SE, KRISTINSSON A, MCINNES GT, MEHLSEN J, NIEMINEN M, O'BRIEN E, OSTERGREN J; ASCOT INVESTIGATORS: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003.
27. THUNSDALL-PEDOE H, KUULASMAA K, TOLONEN H, DAVIDSON M, MENDIS S: MONICA monograph and multimedia sourcebook. H THUNSDAL-PEDOE (ed), World Health Organisation, Geneva, 2003.
28. VRABLIK M, CESKA R, ADAMKOVA V, PEASEY A, PIKHART H, KUBINOVA R, MARMOT M, BOBAK M, HUBACEK JA: MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. Hum Genet 124: 553-555, 2008.
29. WANG K, LI M, HAKONARSON H: Analysing biological pathways in genome-wide association studies. Nat Rev Genet 11: 843-854, 2010.
30. WATERWORTH DM, RICKETTS SL, SONG K, CHEN L, ZHAO JH, RIPATTI S, AULCHENKO YS, ZHANG W, YUAN X, LIM N, LUAN J, ASHFORD S, WHEELER E, YOUNG EH, HADLEY D, THOMPSON JR, BRAUND PS, JOHNSON T, STRUCHALIN M, SURAKKA I, LUBEN R, KHAW KT, RODWELL SA, LOOS RJ, BOEKHOLDT SM, INOUYE M, DELOUKAS P, ELLIOTT P, SCHLESSINGER D, SANNA S, SCUTERI A, JACKSON A, MOHLKE KL, TUOMILEHTO J, ROBERTS R, STEWART A, KESÄNIEMI YA, MAHLEY RW, GRUNDY SM; WELLCOME TRUST CASE CONTROL CONSORTIUM, MCARDLE W, CARDON L, WAEBER G, VOLLENWEIDER P, CHAMBERS JC, BOEHNKE M, ABECASIS GR, SALOMAA V, JÄRVELIN MR, RUOKONEN A, BARROSO I, EPSTEIN SE, HAKONARSON HH, RADER DJ, REILLY MP, WITTEMAN JC, HALL AS, SAMANI NJ, STRACHAN DP, BARTER P, VAN DUIJN CM, KOONER JS, PELTONEN L, WAREHAM NJ, MCPHERSON R, MOOSER V, SANDHU MS: Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 30: 2264-2276, 2010.